KPTI Karyopharm Therapeutics Inc.
Healthcare$8.16+1.24%ClosedMarket Cap: $69.7M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.68
P/S
0.46
EV/EBITDA
-1.27
DCF Value
$-76.34
FCF Yield
-84.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.0%
Operating Margin
-55.7%
Net Margin
-129.0%
ROE
73.1%
ROA
-148.4%
ROIC
-177.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $35.1M | 96.1% | $-26.8M | $-22.4M | $— | — |
| Q4 null | $34.1M | 95.6% | $-17.8M | $-102.2M | $— | — |
| FY null | $146.1M | 95.9% | $-90.7M | $-196.0M | $— | — |
| Q3 null | $44.0M | 95.2% | $-15.2M | $-33.1M | $— | — |
| Q2 null | $37.9M | 97.2% | $-24.4M | $-37.3M | $— | — |
| Q1 null | $30.0M | 95.7% | $-33.3M | $-23.5M | $— | — |
| Q4 null | $30.5M | 95.6% | $-31.3M | $-30.8M | $— | — |
| FY null | $145.2M | 95.9% | $-119.4M | $-76.4M | $— | — |
| Q3 null | $38.8M | 96.6% | $-26.3M | $-32.1M | $— | — |
| Q2 null | $42.8M | 96.4% | $-28.1M | $23.8M | $— | — |
| Q1 null | $33.1M | 94.0% | $-33.8M | $-37.4M | $— | — |
| Q4 2023 | $33.7M | 95.4% | $-37.8M | $-41.8M | $-5.47 | — |